Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional ...

Building on clinical data from millions of individuals who received lipid-encapsulated mRNA vaccines, the FDA has issued new guidance that could facilitate a faster transition to first-in-human trials ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...

Adoption of Triple Combination Therapy Accelerates at Unprecedented Rates as Precision Medicine Revolution ContinuesRockville, MD, Jan. 29, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.